{'52WeekChange': 0.35666668,
 'SandP52WeekChange': 0.0644362,
 'address1': '116 Huntington Avenue',
 'address2': '6th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 20.91,
 'askSize': 900,
 'averageDailyVolume10Day': 33475,
 'averageVolume': 87888,
 'averageVolume10days': 33475,
 'beta': None,
 'beta3Year': None,
 'bid': 18.2,
 'bidSize': 900,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 20.705,
 'dayLow': 18.995,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 245790464,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 32.458286,
 'fiftyTwoWeekHigh': 62.71,
 'fiftyTwoWeekLow': 13.4,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 3937354,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 16,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.24204001,
 'heldPercentInstitutions': 0.46393,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/imaratx.com',
 'longBusinessSummary': 'Imara, Inc., a clinical-stage biopharmaceutical '
                        'company, develops and commercializes therapeutics for '
                        'patients with rare genetic disorders of hemoglobin. '
                        'It develops IMR-687, which is an oral, once-a-day '
                        'therapeutic for the treatment of sickle cell disease '
                        'and b-thalassemia. The company was founded in 2016 '
                        'and is headquartered in Boston, Massachusetts.',
 'longName': 'IMARA Inc.',
 'market': 'us_market',
 'marketCap': 351658176,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_331138302',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -34342000,
 'nextFiscalYearEnd': 1640908800,
 'open': 20.19,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617-206-2020',
 'previousClose': 20.1,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 20.705,
 'regularMarketDayLow': 18.995,
 'regularMarketOpen': 20.19,
 'regularMarketPreviousClose': 20.1,
 'regularMarketPrice': 20.19,
 'regularMarketVolume': 27225,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 17280500,
 'sharesPercentSharesOut': 0.0074,
 'sharesShort': 127385,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 32787,
 'shortName': 'IMARA Inc.',
 'shortPercentOfFloat': 0.0168,
 'shortRatio': 0.76,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'IMRA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 25.250532,
 'volume': 27225,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://imaratx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02116'}